Advertisement
Advertisement
U.S. markets open in 4 hours 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Summit Therapeutics Inc. (SMMT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9816-0.0284 (-2.81%)
At close: 04:00PM EDT
1.0500 +0.07 (+6.97%)
After hours: 07:31PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • J
    John
    Who’s participating?
  • C
    CHRIS
    @Truth- What is your prediction with SMMT
  • T
    Truth
    Be Lookin Good.
    Bullish
  • T
    Truth
    Something's Brewing Team Summit.
    Bullish
  • T
    Truth
    Let's Go Summit
    Bullish
  • T
    Truth
    He Found the Egg 🤷‍♂️
    Bullish
  • j
    jeffrey
    200million shares soon to be outstanding dilution and all that $ going to those 2 and shareholders left holding the colon—— bag. Soon to be reversed split and left in cemetary
  • j
    jeffrey
    Dodge coin is at it again
  • D
    DTM
    85% inside ownership plus great experienced pro investor management Any kind of good news and this explodes to the upside.

    Get in now, because in a couple months this is gonna be out of reach.
  • A
    American Muse
    What's up? Something is surely cooking... This 18% spike in SMMT stock price today on 20 times (2000%) volume is astonishing! This could not be simply because Summit CEO and Chairman Bob Duggan, a successful Pharma Executive, Scientologist, and Venture Capitalist invested another $50 million of his own money in this company. That is old news, the deal was completed one week ago, and cannot be the driver for today's stock action. Is something up with Ridinilazole?
  • K
    Kim
    $SRPT conversation
    Nearly all Sarepta followers saw this coming.
    More
    Bio Stocks™ Retweeted Bio Stocks™
    $SMMT Ezutromid Development to be Discontinued.Bio Stocks™ added,
  • M
    Morgan
    RMANF New Cannabis Alternative Jumps 21% during Mondays session
    Roadman Investments Investee Champignon Brands to Develop Mushroom-infused Cold Brew Coffee in Collaboration With Drip Coffee Social Ltd.
    In late September, RMANF announced that the Company’s investee Champignon Brands Inc. (“Champignon”) has entered into a Product Formulation and R&D Agreement (the “Agreement”) with Nanaimo, B.C. based Drip Coffee Social Ltd. (“Drip Coffee”).
    https://www.tradingview.com/chart/RMANF/aVxRVylL-RMANF-New-Cannabis-Alternative-Jumps-21-during-Mondays-session/
    ===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0450 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying t
    ===================== Roadman Investments Corp. (RMANF) Alert Price: $0.0450 Investor Presentation Website | Recent News ======================== Members, As cannabis legalization spreads across the globe, another mind-altering drug is trying t
    www.tradingview.com
  • m
    mike
    Clearly the Investors at yesterday’s conference were not impressed with him. He should give up doing presentations and stop praising the competition.
  • A
    Anonymous
    EOY results now published on 11th April (this Wednesday) + CONFERENCE CALL
  • A
    Anonymous
    Absolutely correct Mike ... I just took a look and analysts anticipating results 4th April.
  • m
    mike
    Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on 21 June 2018 at 9:30am EDT in New York City.
  • m
    mike
    Wow EOY results better than I thought, now for the CC
  • A
    Anonymous
    Here's a quick resume for NEW READERS! In terms of SMMT investment. What's clear - right here - right now, is that if you had $100 to invest today, Summit's current market cap of $220 million may well be worth $2 billion by end of year. ie if EZD 48 wk trials (results due July / Aug) simply follow on from 24 wk data (see results published in January) and EZD is taken to FDA who will likely approve it on qMR "endpoint" info alone, (See latest FDA approval terms for endorsement - MRI and biomarker info is now endpoint of choice) ... one can assume that the drug value would likely be $2 billion. I base this conservative figure on a company like Sarepta with a fix for only 13% DMD boys achieving mkt cap $5 Billion. Summit has a fix intended for 100% boys. However Summit have valued their treatment on the market at being around $100,000 per boy, per year as opposed to for example Sarepta who are currently charging $300,000 per boy per year. $2 billion is therefore a conservative comparison IMO.

    If this drug is then made available for 100% of DMD boys and mrkt cap is say $2 billion ... investment of $100 would be X 10 by year end = $1000.

    IMO the only risk folk are taking here is the very remote possibility that EZD 24 wk data was some fluke. (So there is a small risk still attached) We know the trial has been completed and NO safety issues. Just slight improvement in figures (continued build up off drug most likely to show improvement) will most likely result in a pass for qMR endpoint and in response the 6MWT and ambulatory functions will show actual positive effect. (Though as in Sarepta's case this was only shown to be tiny improvement at end of P2 ... not IMO relying on those figures which have historically been hard to show elsewhere)

    We also know that this drug will in principle help Becker MD sufferers ... that's the same number of sufferers again. Summit will also carry on increasing in value as C Diff and Gonorrhea drugs complete trials. C Diff has already passed P2 and shown to be very best in class .... keeping thousands of people alive who simply go into hospitals and pick up C Diff whilst undergoing routine operations. C Diff P3 trials 2019. Over the next few years millions will die from this without help.

    If I were to recommend someone investing $100 where to put it "right here - right now" ... there aren't many companies capable of such reward with this low risk. However ....DYOR.
Advertisement
Advertisement